Many radiographic studies and procedures use iodinated contrast media and consequently pose the risk of contrast-induced acute kidney injury (AKI). This is an important complication, which accounts for a significant number of cases of hospital-acquired renal failure associated increased hospital length of stay and increased mortality. Sustained reductions in renal blood flow, hypoxic injury, direct cellular toxicity by the contrast media, and superimposed organ injury are all believed to play a role in this form of AKI. Avoidance of dehydration and multimodality prevention measures may reduce rates of this problem in patients at risk. Contrast-induced AKI is likely to remain a significant challenge for specialists in the future since the patient population is aging, chronic kidney disease and diabetes are coming more common, and use of iodinated contrast is growing.

Keywords:
Acute kidney injury, Iodinated contrast, Chronic kidney disease, Cardiovascular disease, Porphylaxis, Osmolality
1.
McCullough PA, Soman SS: Contrast-induced nephropathy. Crit Care Clin 2005;21:261–280.
2.
Gleeson TG, Bulugahapitiya S: Contrast-induced nephropathy. AJR Am J Roentgenol 2004;183:1673–1689.
3.
Nash K, Hafeez A, Hou S: Hospital-acquired renal insufficiency. Am J Kidney Dis 2002;39:930–936.
4.
Chew DP, Astley C, Molloy D, et al: Morbidity, mortality and economic burden of renal impairment in cardiac intensive care. Intern Med J 2006;36:185–192.
5.
Bagshaw SM, Mortis G, Doig CJ, et al: One-year mortality in critically ill patients by severity of kidney dysfunction: a population-based assessment. Am J Kidney Dis 2006;48:402–409.
6.
Becker CR, Davidson C, Lameire N, et al: High-risk situations and procedures. Am J Cardiol 2006;98:37K–41K.
7.
Davidson C, Stacul F, McCullough PA, et al: Contrast medium use. Am J Cardiol 2006;98:42K–58K.
8.
Lameire N, Adam A, Becker CR, et al: Baseline renal function screening. Am J Cardiol 2006;98:21K–26K.
9.
McCullough PA, Adam A, Becker CR, et al: Risk prediction of contrast-induced nephropathy. Am J Cardiol 2006;98:27K–36K.
10.
Stacul F, Adam A, Becker CR, et al: Strategies to reduce the risk of contrast-induced nephropathy. Am J Cardiol 2006;98:59K–77K.
11.
Tumlin J, Stacul F, Adam A, et al: Pathophysiology of contrast-induced nephropathy. Am J Cardiol 2006;98:14K–20K.
12.
McCullough PA, Adam A, Becker CR, et al: Epidemiology and prognostic implications of contrast-induced nephropathy. Am J Cardiol 2006;98:5K–13K.
13.
McCullough PA, Stacul F, Davidson C, et al: Overview. Am J Cardiol 2006;98:2K–4K.
14.
Thomsen HS: Guidelines for contrast media from the European Society of Urogenital Radiology. AJR Am J Roentgenol 2003;181:1463–1471.
15.
Bartholomew BA, Harjai KJ, Dukkipati S, et al: Impact of nephropathy after percutaneous coronary intervention and a method for risk stratification. Am J Cardiol 2004;93:1515–1519.
16.
Hou SH, Bushinsky DA, Wish JB, et al: Hospital-acquired renal insufficiency: a prospective study. Am J Med 1983;74:243–248.
17.
McCullough PA, Wolyn R, Rocher LL, et al: Acute renal failure after coronary intervention: incidence, risk factors, and relationship to mortality. Am J Med 1997;103:368–375.
18.
Iakovou I, Dangas G, Mehran R, et al: Impact of gender on the incidence and outcome of contrast-induced nephropathy after percutaneous coronary intervention. J Invasive Cardiol 2003;15:18–22.
19.
Polena S, Yang S, Alam R, et al: Nephropathy in critically Ill patients without preexisting renal disease. Proc West Pharmacol Soc 2005;48:134–135.
20.
Haveman JW, Gansevoort RT, Bongaerts AH, et al: Low incidence of nephropathy in surgical ICU patients receiving intravenous contrast: a retrospective analysis. Intensive Care Med 2006;32:1199–1205.
21.
Levy EM, Viscoli CM, Horwitz RI: The effect of acute renal failure on mortality: a cohort analysis. JAMA 1996;275:1489–1494.
22.
Rihal CS, Textor SC, Grill DE, et al: Incidence and prognostic importance of acute renal failure after percutaneous coronary intervention. Circulation 2002;105:2259–2264.
23.
Gruberg L, Mintz GS, Mehran R, et al: The prognostic implications of further renal function deterioration within 48 h of interventional coronary procedures in patients with pre-existent chronic renal insufficiency. J Am Coll Cardiol 2000;36:1542–1548.
24.
Sadeghi HM, Stone GW, Grines CL, et al: Impact of renal insufficiency in patients undergoing primary angioplasty for acute myocardial infarction. Circulation 2003;108:2769–2775.
25.
Marenzi G, Lauri G, Assanelli E, et al: Contrast-induced nephropathy in patients undergoing primary angioplasty for acute myocardial infarction. J Am Coll Cardiol 2004;44:1780–1785.
26.
Lindsay J, Apple S, Pinnow EE, et al: Percutaneous coronary intervention-associated nephropathy foreshadows increased risk of late adverse events in patients with normal baseline serum creatinine. Catheter Cardiovasc Interv 2003;59:338–343.
27.
Lindsay J, Canos DA, Apple S, et al: Causes of acute renal dysfunction after percutaneous coronary intervention and comparison of late mortality rates with postprocedure rise of creatine kinase-MB versus rise of serum creatinine. Am J Cardiol 2004;94:786–789.
28.
Dangas G, Iakovou I, Nikolsky E, et al: Contrast-induced nephropathy after percutaneous coronary interventions in relation to chronic kidney disease and hemodynamic variables. Am J Cardiol 2005;95:13–19.
29.
Subramanian S, Tumlin J, Bapat B, et al: Economic burden of contrast-induced nephropathy: implications for prevention strategies. J Med Econ 2007;10:119–134.
30.
Freeman RV, O’Donnell M, Share D, et al: Nephropathy requiring dialysis after percutaneous coronary intervention and the critical role of an adjusted contrast dose. Am J Cardiol 2002;90:1068–1073.
31.
Birck R, Krzossok S, Markowetz F, et al: Acetylcysteine for prevention of contrast nephropathy: meta-analysis. Lancet 2003;362:598–603.
32.
Martin-Paredero V, Dixon SM, Baker JD, et al: Risk of renal failure after major angiography. Arch Surg 1983;118:1417–1420.
33.
Gomes AS, Baker JD, Martin-Paredero V, et al: Acute renal dysfunction after major arteriography. AJR Am J Roentgenol 1985;145:1249–1253.
34.
Nikolsky E, Mehran R, Turcot DB, et al: Impact of chronic kidney disease on prognosis of patients with diabetes mellitus treated with percutaneous coronary intervention. Am J Cardiol 2004;94:300–305.
35.
Davidson CJ, Hlatky M, Morris KG, et al: Cardiovascular and renal toxicity of a nonionic radiographic contrast agent after cardiac catheterization. A prospective trial. Ann Intern Med 1989;110:119–124.
36.
K/DOQI Clinical Practice Guidelines for Chronic Kidney Disease: Evaluation, classification, and stratification. Am J Kidney Dis 2002;39(2 suppl 1):S1–S266.
37.
Tippins RB, Torres WE, Baumgartner BR, et al: Are screening serum creatinine levels necessary prior to outpatient CT examinations? Radiology 2000;216:481–484.
38.
Choyke PL, Cady J, DePollar SL, et al: Determination of serum creatinine prior to iodinated contrast media: is it necessary in all patients? Tech Urol 1998;4:65–69.
39.
Olsen JC, Salomon B: Utility of the creatinine prior to intravenous contrast studies in the emergency department. J Emerg Med 1996;14:543–546.
40.
Krumlovsky FA, Simon N, Santhanam S, et al: Acute renal failure: association with administration of radiographic contrast material. JAMA 1978;239:125–127.
41.
Mehran R, Aymong ED, Nikolsky E, et al: A simple risk score for prediction of contrast-induced nephropathy after percutaneous coronary intervention: development and initial validation. J Am Coll Cardiol 2004;44:1393–1399.
42.
Nikolsky E, Mehran R, Lasic Z, et al: Low hematocrit predicts contrast-induced nephropathy after percutaneous coronary interventions. Kidney Int 2005;6:706–713.
43.
Barrett BJ, Carlisle EJ: Meta-analysis of the relative nephrotoxicity of high- and low-osmolality iodinated contrast media. Radiology 1993;188:171–178.
44.
Rudnick MR, Goldfarb S, Wexler L, et al: Nephrotoxicity of ionic and nonionic contrast media in 1196 patients: a randomized trial. The Iohexol Cooperative Study. Kidney Int 1995;47:254–261.
45.
Aspelin P, Aubry P, Fransson SG, et al: Nephrotoxic effects in high-risk patients undergoing angiography. N Engl J Med 2003;348:491–499.
46.
Chalmers N, Jackson RW: Comparison of iodixanol and iohexol in renal impairment. Br J Radiol 1999;72:701–703.
47.
McCullough PA, Bertrand ME, Brinker JA, et al: A meta-analysis of the renal safety of isosmolar iodixanol compared with low-osmolar contrast media. J Am Coll Cardiol 2006;48:692–699.
48.
Solomon R: The role of osmolality in the incidence of contrast-induced nephropathy: a systematic review of angiographic contrast media in high risk patients. Kidney Int 2005;68:2256–2263.
49.
Clauss W, Dinger J, Meissner C: Renal tolerance of iotrolan 280: a meta analysis of 14 double-blind studies. Eur Radiol 1995;5:S79–S84.
50.
Jo SH, Youn TJ, Koo BK, et al: Renal toxicity evaluation and comparison between visipaque (iodixanol) and hexabrix (ioxaglate) in patients with renal insufficiency undergoing coronary angiography: the RECOVER study: a randomized controlled trial. J Am Coll Cardiol 2006;48:924–930.
51.
Barrett BJ, Katzberg RW, Thomsen HS, et al: Contrast-induced nephropathy in patients with chronic kidney disease undergoing computed tomography: a double-blind comparison of iodixanol and iopamidol. Invest Radiol 2006;41:815–821.
52.
Solomon RJ, Natarajan MK, Doucet S, et al: Cardiac Angiography in Renally Impaired Patients (CARE) study: a randomized double-blind trial of contrast-induced nephropathy in patients with chronic kidney disease. Circulation 2007;115:3189–3196.
53.
Anderson JL, Adams CD, Antman EM, Bridges CR, Califf RM, Casey DE Jr, Chavey WE 2nd, Fesmire FM, Hochman JS, Levin TN, Lincoff AM, Peterson ED, Theroux P, Wenger NK, Wright RS, Smith SC Jr, Jacobs AK, Adams CD, Anderson JL, Antman EM, Halperin JL, Hunt SA, Krumholz HM, Kushner FG, Lytle BW, Nishimura R, Ornato JP, Page RL, Riegel B: ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction-Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction) Developed in Collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons Endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine. J Am Coll Cardiol 2007;50:652–726.
54.
Manske CL, Sprafka JM, Strony JT, et al: Contrast nephropathy in azotemic diabetic patients undergoing coronary angiography. Am J Med 1990;89:615–620.
55.
Laskey WK, Jenkins C, Selzer F, Marroquin OC, Wilensky RL, Glaser R, Cohen HA, Holmes DR Jr, NHLBI Dynamic Registry Investigators: Volume-to-creatinine clearance ratio: a pharmacokinetically based risk factor for prediction of early creatinine increase after percutaneous coronary intervention. J Am Coll Cardiol 2007;50:584–90. Epub 2007 Jul 30.
56.
Campbell DR, Flemming BK, Mason WF, et al: A comparative study of the nephrotoxicity of iohexol, iopamidol and ioxaglate in peripheral angiography. Can Assoc Radiol J 1990;41:133–137.
57.
Moore RD, Steinberg EP, Powe NR, et al: Nephrotoxicity of high-osmolality versus low-osmolality contrast media: randomized clinical trial. Radiology 1992;182:649–655.
58.
Mueller C, Buerkle G, Buettner HJ, et al: Prevention of contrast media-associated nephropathy: randomized comparison of 2 hydration regimens in 1620 patients undergoing coronary angioplasty. Arch Intern Med 2002;162:329–336.
59.
Merten GJ, Burgess WP, Gray LV, et al: Prevention of contrast-induced nephropathy with sodium bicarbonate: a randomized controlled trial. JAMA 2004;291:2328–2334.
60.
Brar S: A randomized controlled trial for the prevention of contrast induced nephropathy with sodium bicarbonate vs. sodium chloride in persons undergoing coronary angiography (the MEENA trial). Abstract 209-9. 56th Annual Scientific Session of the American College of Cardiology, New Orleans, 2007, pp 24–27.
61.
Stevens MA, McCullough PA, Tobin KJ, et al: A prospective randomized trial of prevention measures in patients at high risk for contrast nephropathy: results of the P.R.I.N.C.E. study. J Am Coll Cardiol 1999;33:403–411.
62.
Taylor AJ, Hotchkiss D, Morse RW, et al: PREPARED: Preparation for Angiography in Renal Dysfunction: a randomized trial of inpatient vs outpatient hydration protocols for cardiac catheterization in mild-to-moderate renal dysfunction. Chest 1998;114:1570–1574.
63.
Marenzi G, Marana I, Lauri G, et al: The prevention of radiocontrast-agent-induced nephropathy by hemofiltration. N Engl J Med 2003;349:1333–1340.
64.
Marenzi G, Lauri G, Campodonico J, Marana I, Assanelli E, De Metrio M, Grazi M, Veglia F, Fabbiocchi F, Montorsi P, Bartorelli AL: Comparison of two hemofiltration protocols for prevention of contrast-induced nephropathy in high-risk patients. Am J Med 2006;119:155–162.
65.
Spargias K, Alexopoulos E, Kyrzopoulos S, Iokovis P, Greenwood DC, Manginas A, Voudris V, Pavlides G, Buller CE, Kremastinos D, Cokkinos DV: Ascorbic acid prevents contrast-mediated nephropathy in patients with renal dysfunction undergoing coronary angiography or intervention. Circulation 2004;110:2837–2842.
66.
Birck R, Krzossok S, Makowetz F, Schnulle P, van der Woude F, Braun C: Acetylcysteine for prevention of contrast nephropathy: meta-analysis. Lancet 2003;362:598–603.
67.
Isenbarger D, Kent S, O’Malley P: Meta-analysis of randomized clinical trials on the usefulness of acetylcysteine for prevention of contrast nephropathy. Am J Cardiol 2003;92:1454–1458.
68.
Alonso A, Lau J, Jaber B, Weintraub A, Sarnak M: Prevention of radiocontrast nephropathy with N-acetylcysteine in patients with chronic kidney disease: a meta-analysis of randomized, controlled trials. Am J Kidney Dis 2004;43:1–9.
69.
Kshirsagar A, Poole C, Mottl A, Shoham D, Franceschini N, Tudor G, Agrawal M, Denu-Ciocca C, Magnus Ohman E, Finn WF: N-acetylcysteine for the prevention of radiocontrast induced nephropathy: a meta-analysis of prospective controlled trials. J Am Soc Nephrol 2004;15:761–769.
70.
Pannu N, Manns B, Lee H, Tonelli M: Systematic review of the impact of N-acetylcysteine on contrast nephropathy. Kidney Int 2004;65:1366–1374.
71.
Guru V, Fremes S: The role of N-acetylcysteine in preventing radiographic contrast-induced nephropathy. Clin Nephrol 2004;62:77–83.
72.
Bagshaw S, Ghali WA: Acetylcysteine for prevention of contrast-induced nephropathy: a systematic review and meta-analysis. BMC Med 2004;2:38.
73.
Misra D, Leibowitz K, Gowda R, Shapiro M, Khan I: Role of N-acetylcysteine in prevention of contrast-induced nephropathy after cardiovascular procedures: a meta-analysis. Clin Cardiol 2004;27:607–610.
74.
Nallamothu BK, Shojania KG, Saint S, Hofer TP, Humes HD, Moscucci M, Bates ER: Is acetylcysteine effective in preventing contrast-related nephropathy? A meta-analysis. Am J Med 2004;117:938–947.
75.
Liu R, Nair D, Ix J, Moore D, Bent S: N-acetylcysteine for prevention of contrast-induced nephropathy: a systematic review and meta-analysis. J Gen Intern Med 2005;20:193–200.
76.
Duong M, MacKenzie T, Malenka D: N-acetylcysteine prophylaxis significantly reduces the risk of radiocontrast-induced nephropathy. Catheter Cardiovasc Interv 2005;64:471–479.
77.
Bagshaw SM, McAlister FA, Manns BJ, Ghali WA: Acetylcysteine in the prevention of contrast-induced nephropathy: a case study of the pitfalls in the evolution of evidence. Arch Intern Med 2006;166:161–166.
78.
Marenzi G, Assanelli E, Marana I, Lauri G, Campodonico J, Grazi M, De Metrio M, Galli S, Fabbiocchi F, Montorsi P, Veglia F, Bartorelli AL: N-acetylcysteine and contrast-induced nephropathy in primary angioplasty. N Engl J Med 2006;354:2773–2782.
79.
Briguori C, Airoldi F, D’Andrea D, et al: Renal insufficiency following contrast media administration Trial (REMEDIAL): a randomized comparison of 3 preventive strategies. Circulation 2007;115:1211–1217.
80.
Khanal S, Attallah N, Smith DE, Kline-Rogers E, Share D, O’Donnell MJ, Moscucci M: Statin therapy reduces contrast-induced nephropathy: an analysis of contemporary percutaneous interventions. Am J Med 2005;118:843–849.
81.
Chello M, Barbato R, Patti G, Goffredo C, di Sciasco G, Covino E: Prevention of postoperative acute renal failure by statin therapy in patients undergoing cardiac surgery. J Am Coll Cardiol 2007; in press.
82.
McCullough PA, Rocher LR: Statin therapy in renal disease: harmful or protective. Curr Atheroscler Rep 2007;9:18–24.
83.
Bachorzewska-Gajewska H, Malyszko J, Sitniewska E, Malyszko JS, Dobrzycki S: Neutrophil-gelatinase-associated lipocalin and renal function after percutaneous coronary interventions. Am J Nephrol 2006;26:287–92. Epub 2006 Jun 13.
84.
Mishra J, Dent C, Tarabishi R, Mitsnefes MM, Ma Q, Kelly C, Ruff SM, Zahedi K, Shao M, Bean J, Mori K, Barasch J, Devarajan P: Neutrophil gelatinase-associated lipocalin (NGAL) as a biomarker for acute renal injury after cardiac surgery. Lancet 2005;365:1231–1238.
85.
Movahed MR, Wong J, Molloi S: Removal of iodine contrast from coronary sinus in swine during coronary angiography. J Am Coll Cardiol 2006;47:465–467.
86.
Michishita I, Fujii Z: A novel contrast removal system from the coronary sinus using an adsorbing column during coronary angiography in a porcine model. J Am Coll Cardiol 2006;47:1866–1870.
© 2008 S. Karger AG, Basel
2008
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.